PAP
PRAX icon

Persistent Asset Partners’s Praxis Precision Medicines PRAX Stock Holding History

Persistent Asset Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-230
Closed -$15.6K – 444
2025
Q4 		$15.6K Hold
230
– – 0.01% 319
2025
Q3 		$319K Buy
+230
New +$11.2K 0.22% 104

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Persistent Asset Partners's PRAX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Praxis Precision Medicines (PRAX) stake by 20% in Q1 2026, selling an estimated $85.4K and leaving 1,131 shares worth $364K. The position accounts for 0.14% of the portfolio, ranked #135.

Persistent Asset Partners first reported a position in PRAX in Q4 2025 and has held it in 2 quarters since. The position peaked at $415K in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Persistent Asset Partners held 1,131 shares of Praxis Precision Medicines worth $364K as of Q1 2026.
  • Persistent Asset Partners sold 276 Praxis Precision Medicines shares in Q1 2026, an estimated $85.4K.
  • Praxis Precision Medicines made up 0.14% of Persistent Asset Partners's portfolio in Q1 2026, its #135 holding.
  • Persistent Asset Partners first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Praxis Precision Medicines position peaked at $415K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.